drugset
drugset / Trial / NCT03011333

Phase 2B Upper Extremity Nerve Block Study

NCT03011333 ↗

Phase 2 Completed 243 enrolled Heron Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 2B, randomized, assessor-blind, active- and saline placebo-controlled, multicenter study in subjects undergoing augmentation mammoplasty to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 when administered via ultrasound-guided lateral and medial pectoral nerve block before surgery.

Timeline

Start
2017-01-14
Primary completion
2018-02-01
Completion
2018-03-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 50 mg Other
Subject HTX-011 Unknown 60 mg Other
Subject HTX-011 Unknown 120 mg Other
Subject HTX-011 Unknown 240 mg Other
Subject HTX-011 Unknown 400 mg Other

Indications

No indication recorded.